Journal article
Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704
Abstract
Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC …
Authors
Puvvada SD; Stiff PJ; Leblanc M; Cook JR; Couban S; Leonard JP; Kahl B; Marcellus D; Shea TC; Winter JN
Journal
British Journal of Haematology, Vol. 174, No. 5, pp. 686–691
Publisher
Wiley
Publication Date
September 2016
DOI
10.1111/bjh.14100
ISSN
0007-1048
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsAutograftsCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHematopoietic Stem Cell TransplantationHumansLymphomaMaleMiddle AgedPrednisoneProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycRituximabTreatment OutcomeVincristineYoung Adult